Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
134.89
-2.17 (-1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
57
58
Next >
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
Today 13:59 EDT
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare...
Via
Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Today 13:56 EDT
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while...
Via
Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
Today 3:47 EDT
A small telemedicine company just entered the weight loss race.
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in Novo Nordisk
August 15, 2024
Via
Benzinga
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
There are a number of pharmaceutical companies looking to make waves in the weight loss market.
Via
The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
The unveiled prices follow months of back-and-forth negotiation between the government and the companies.
Via
Investor's Business Daily
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
August 15, 2024
Novo Nordisk still expects to see a lot more growth in the second half.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
August 14, 2024
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
August 14, 2024
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection...
Via
Benzinga
3 Stable Blue-Chip Stocks to Buy for the Market Storm
August 14, 2024
Looking to shield your assets and protect your portfolio amid the current market volatility? Take refuge in these reliable stocks.
Via
InvestorPlace
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
August 14, 2024
One player's minor pain is another's moderate gain.
Via
The Motley Fool
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
August 13, 2024
Eli Lilly stock and Novo Nordisk kicked off the vanity trade, but the "me-conomy" trend is extending to other industries as well.
Via
Investor's Business Daily
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
August 13, 2024
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility.
Via
InvestorPlace
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
August 13, 2024
There's reason to believe some of its expected revenue will take longer to arrive.
Via
The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
August 13, 2024
A company's investments can easily ruin the plans of its competitors.
Via
The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
August 12, 2024
GLP-1 agonists like Ozempic and Wegovy, known for treating obesity and diabetes, are now showing potential in reducing cancer risk, particularly for cancers linked to obesity. New research highlights...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
August 12, 2024
The company's addressable market could eventually be expanded even more.
Via
The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
August 10, 2024
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
August 09, 2024
Eli Lilly's Q2 revenue soared to $11.3 billion, surpassing forecasts. Mounjaro sales tripled and Zepbound revenue grew significantly post-FDA approval. Analysts are cautious about future supply and...
Via
Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
August 09, 2024
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.
Via
MarketBeat
Topics
ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
August 09, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Via
The Motley Fool
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
August 09, 2024
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in.
Via
MarketBeat
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
August 08, 2024
Paying a high premium for Novo Nordisk stock may be justifiable based on the company's significant growth opportunities.
Via
The Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
August 08, 2024
News from a competitor gave investors an unwelcome dose of reality.
Via
The Motley Fool
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
August 07, 2024
Novo Nordisk missed Q2 earnings estimates and announced plans to resubmit Wegovy STEP HFpEF trial results for FDA review in early 2025. Despite strong trial data, the FDA requested more extensive...
Via
Benzinga
Exposures
Product Safety
Stocks To Watch Today: AXON, LYFT, And Novo Nordisk
August 07, 2024
Axon Enterprise saw its stock soar nearly 20% on strong AI service demand, while Lyft and Novo Nordisk shares plummeted due to disappointing financial results.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript
August 07, 2024
NVO earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
August 07, 2024
The U.S.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
57
58
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.